|
CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers. |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Advanced Accelerator Applications |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Nordic Bioscience |
Research Funding - Exact Sciences; Exelixis; Nordic Bioscience; Roche |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Mirati Therapeutics; MSD Oncology; Nouscom; Roche; Seagen; Takeda |
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); MSD Oncology (Inst); Nouscom (Inst); Roche (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Gilead Sciences |
| |
|
|
Stock and Other Ownership Interests - Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Nordic Bioscience |
Research Funding - Exact Sciences; Exelixis; Nordic Bioscience; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca |
| |
|
Employment - CellCentric (I) |
Stock and Other Ownership Interests - CellCentric (I) |
|
|
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Loxo/Lilly (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); UCB (Inst) |
Patents, Royalties, Other Intellectual Property - CUPiD Methylation assay. Patent application has now been filed at the UKIPO. The patent application number is GB2317261.2 (Inst) |
Travel, Accommodations, Expenses - Roche |
(OPTIONAL) Uncompensated Relationships - Roche |